clinical trial · NCT05248230
4D-710 in Adult Patients With Cystic Fibrosis
Cystic Fibrosis Lung4D-710
brief summary
This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with cystic fibrosis.
started
Mar 29, 2022
primary completion
Jun 1, 2027
completion
Jun 1, 2031
last updated
Mar 11, 2026
detailed description
This Phase 1/2 trial will evaluate the safety, tolerability, and preliminary efficacy of 4D-710, an investigational gene therapy, in adults with cystic fibrosis (CF) lung disease who are ineligible or unable to tolerate CFTR modulator therapy. A sub-study will evaluate 4D-710 in a cohort of adults with CF advanced lung disease and/or frequent pulmonary exacerbation (PE) while on currently available CFTR modulator therapy.
official title
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-710 in Adults With Cystic Fibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol